	US 11,833,292 B2
	Drug delivery systems and related methods
Matthew Ferriter, Chapel Hill, NC (US); Denny Himel, Cary, NC (US); Brian Foster, Apex, NC (US); Michael L. King, Durham, NC (US); Dan Deaton, New Hill, NC (US); Fred Hamlin, Cambridge (GB); Jill Sherwood, Raleigh, NC (US); Sarvajna Kumar Dwivedi, Redwood City, CA (US); and Robert V. Sheehy, Jr., N. Attleboro, MA (US)
Assigned to Pearl Therapeutics, Inc., Redwood City, CA (US)
Appl. No. 16/754,585
Filed by Pearl Therapeutics, Inc., Redwood City, CA (US)
PCT Filed Oct. 5, 2018, PCT No. PCT/US2018/054721 § 371(c)(1), (2) Date Apr. 8, 2020, PCT Pub. No. WO2019/074799, PCT Pub. Date Apr. 18, 2019.
Claims priority of provisional application 62/639,911, filed on Mar. 7, 2018.
Claims priority of provisional application 62/569,901, filed on Oct. 9, 2017.
Prior Publication US 2020/0353185 A1, Nov. 12, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61M 15/00 (2006.01); A61M 11/00 (2006.01)

CPC A61M 15/009 (2013.01) [A61M 15/0026 (2014.02); A61M 15/0068 (2014.02); A61M 2202/062 (2013.01)]

20 Claims

1. A drug delivery device comprising: a canister containing a drug formulation and having a discharge valve and a valve stem defining a valve stem passage through which the drug formulation is selectively discharged; a desiccant housing separate and distinct from the canister and removably attached to the canister with the valve stem extending through the desiccant housing; and a desiccant material provided in the desiccant housing in fluid communication with the valve stem passage at least when the valve stem is in an expanded position and the drug formulation is not being discharged from the canister; and a valve stem block including a discharge orifice in fluid communication with an inhalation passageway from which the drug formulation is ejected during an inhalation event after passing through the valve stem passage.